390 related articles for article (PubMed ID: 38256166)
1. Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.
Waseem M; Wang BD
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256166
[TBL] [Abstract][Full Text] [Related]
2. Engineering prostate cancer in vitro: what does it take?
Buskin A; Scott E; Nelson R; Gaughan L; Robson CN; Heer R; Hepburn AC
Oncogene; 2023 Aug; 42(32):2417-2427. PubMed ID: 37438470
[TBL] [Abstract][Full Text] [Related]
3. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
4. [Progress in prostate cancer study: 3D cell culture enables the ex vivo reproduction of tumor characteristics].
Tostivint V; Racaud-Sultan C; Roumiguié M; Soulié M; Gamé X; Beauval JB
Presse Med; 2017 Oct; 46(10):954-965. PubMed ID: 28967525
[TBL] [Abstract][Full Text] [Related]
5. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
6. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer.
Mickova A; Morong M; Levková M; Kurfúrstová D; Kharaishvili G; Überall I; Student V; Student V; Drapela S; Soucek K; Bouchal J
Klin Onkol; 2022; 35(6):473-481. PubMed ID: 36513514
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A; Albino D; Catapano CV; Carbone GM
Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
[TBL] [Abstract][Full Text] [Related]
8. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L; Sabio J; Poiraudeau L; Annereau M; Menssouri N; Helissey C; Déas O; Aglave M; Ibrahim T; Pobel C; Nobre C; Nicotra C; Ngo-Camus M; Lacroix L; Rouleau E; Tselikas L; Judde JG; Chauchereau A; Bernard-Tessier A; Patrikidou A; Naoun N; Flippot R; Colomba E; Fuerea A; Albiges L; Lavaud P; Massard C; Friboulet L; Fizazi K; Besse B; Scoazec JY; Loriot Y
Eur Urol Oncol; 2024 Jun; 7(3):527-536. PubMed ID: 38433714
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.
Servant R; Garioni M; Vlajnic T; Blind M; Pueschel H; Müller DC; Zellweger T; Templeton AJ; Garofoli A; Maletti S; Piscuoglio S; Rubin MA; Seifert H; Rentsch CA; Bubendorf L; Le Magnen C
J Pathol; 2021 Aug; 254(5):543-555. PubMed ID: 33934365
[TBL] [Abstract][Full Text] [Related]
10. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Beshiri ML; Tice CM; Tran C; Nguyen HM; Sowalsky AG; Agarwal S; Jansson KH; Yang Q; McGowen KM; Yin J; Alilin AN; Karzai FH; Dahut WL; Corey E; Kelly K
Clin Cancer Res; 2018 Sep; 24(17):4332-4345. PubMed ID: 29748182
[No Abstract] [Full Text] [Related]
11. Application of Organoid Models in Prostate Cancer Research.
Zhou L; Zhang C; Zhang Y; Shi C
Front Oncol; 2021; 11():736431. PubMed ID: 34646778
[TBL] [Abstract][Full Text] [Related]
12. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
[TBL] [Abstract][Full Text] [Related]
13. Patient derived organoids to model rare prostate cancer phenotypes.
Puca L; Bareja R; Prandi D; Shaw R; Benelli M; Karthaus WR; Hess J; Sigouros M; Donoghue A; Kossai M; Gao D; Cyrta J; Sailer V; Vosoughi A; Pauli C; Churakova Y; Cheung C; Deonarine LD; McNary TJ; Rosati R; Tagawa ST; Nanus DM; Mosquera JM; Sawyers CL; Chen Y; Inghirami G; Rao RA; Grandori C; Elemento O; Sboner A; Demichelis F; Rubin MA; Beltran H
Nat Commun; 2018 Jun; 9(1):2404. PubMed ID: 29921838
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived organoids as a model for tumor research.
Wang J; Feng X; Li Z; Chen Y; Huang W
Prog Mol Biol Transl Sci; 2022; 189(1):259-326. PubMed ID: 35595351
[TBL] [Abstract][Full Text] [Related]
15. Tumor organoids: applications in cancer modeling and potentials in precision medicine.
Xu H; Jiao D; Liu A; Wu K
J Hematol Oncol; 2022 May; 15(1):58. PubMed ID: 35551634
[TBL] [Abstract][Full Text] [Related]
16. Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research.
Elbadawy M; Abugomaa A; Yamawaki H; Usui T; Sasaki K
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218271
[TBL] [Abstract][Full Text] [Related]
17. Cancer organoid co-culture model system: Novel approach to guide precision medicine.
Yuan J; Li X; Yu S
Front Immunol; 2022; 13():1061388. PubMed ID: 36713421
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.
Li J; Liu J; Xia W; Yang H; Sha W; Chen H
Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190
[TBL] [Abstract][Full Text] [Related]
19. Current experimental human tissue-derived models for prostate cancer research.
Kato M; Sasaki T; Inoue T
Int J Urol; 2021 Feb; 28(2):150-162. PubMed ID: 33247498
[TBL] [Abstract][Full Text] [Related]
20. High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.
Choo N; Ramm S; Luu J; Winter JM; Selth LA; Dwyer AR; Frydenberg M; Grummet J; Sandhu S; Hickey TE; Tilley WD; Taylor RA; Risbridger GP; Lawrence MG; Simpson KJ
SLAS Discov; 2021 Oct; 26(9):1107-1124. PubMed ID: 34111999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
